8-K: Myomo Secures $3 Million Term Loan Facility with Silicon Valley Bank

Myomo, Inc. has entered into an amendment to its loan agreement with Silicon Valley Bank, securing a new term loan facility of up to $3 million to bolster its financial position.

Summary

• Myomo, Inc. has amended its loan agreement with Silicon Valley Bank to include a new term loan facility.
• The term loan provides Myomo with access to up to $3 million until February 28, 2026.
• Advances under the term loan will be repaid in 36 equal monthly installments starting March 1, 2026, with all remaining obligations due on February 1, 2029.
• The interest rate on the term loan will be the greater of 5.0% or the prime rate (as published in the Wall Street Journal) minus 1.0%.
• Myomo has the option to prepay the term loan, subject to a prepayment premium ranging from 1.0% to 3.0%, depending on the year of prepayment, and an end of term charge equal to 2.50% of the aggregate principal amount of any loans prepaid or repaid.
• The amendment also includes changes to Myomo's revolving line of credit, increasing the limit for Medicare receivables and the permitted balance in its German subsidiary.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Myomo as it secures additional financing. While there are costs associated with the loan, it provides the company with increased financial flexibility. The sentiment is moderately positive.

Positives

• Myomo gains access to additional capital through the $3 million term loan facility.
• The increased limit for Medicare receivables under the revolving line of credit provides more flexibility.
• The increased permitted balance in the German subsidiary allows for greater operational flexibility.

Negatives

• The term loan incurs interest at a floating rate, which could increase if the prime rate rises.
• Prepayment of the term loan is subject to a premium, potentially increasing the cost of early repayment.
• The term loan includes an end of term charge equal to 2.50% of the aggregate principal amount of any loans prepaid or repaid.

Risks

• Fluctuations in the prime rate could impact the interest expense on the term loan.
• Myomo's ability to repay the term loan depends on its future financial performance.
• Failure to comply with the loan agreement terms could trigger an event of default.

Future Outlook

The term loan facility provides Myomo with additional financial resources to support its operations and growth initiatives. The company's ability to draw on the loan and meet its repayment obligations will depend on its future financial performance.

Industry Context

In the current economic climate, securing financing can be crucial for companies like Myomo to fund operations and growth. This agreement reflects confidence from Silicon Valley Bank in Myomo's business prospects. Other companies in the medical device sector may be facing similar financing needs and seeking comparable arrangements.

Comparison to Industry Standards

• Term loan interest rates for companies like Myomo typically range from prime plus 1% to prime plus 5%, making Myomo's rate of prime minus 1% relatively favorable.
• Prepayment penalties are standard in term loan agreements, often ranging from 1% to 3% of the outstanding principal.
• Comparable companies, such as Ekso Bionics and ReWalk Robotics, have also utilized debt financing to support their operations and growth.
• The size of the term loan is consistent with the financing needs of a company of Myomo's size and stage of development.

Stakeholder Impact

• Shareholders: The new financing provides Myomo with additional capital, which could support growth and increase shareholder value.
• Employees: Access to capital can help ensure the stability of the company and support continued employment.
• Customers: The financing can enable Myomo to continue providing its products and services to customers.
• Suppliers: The financing can help Myomo meet its obligations to suppliers.
• Creditors: The new term loan adds to Myomo's debt obligations.

Next Steps

• Myomo can draw on the term loan facility until February 28, 2026.
• The company will begin making monthly principal and interest payments on March 1, 2026.
• Myomo will need to monitor its financial performance to ensure it can meet its repayment obligations.

Key Dates